# Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

> **NCT05465174** · PHASE2 · RECRUITING · sponsor: **Sabine Mueller, MD, PhD** · enrollment: 57 (estimated)

## Conditions studied

- Craniopharyngioma, Child
- Craniopharyngioma
- Recurrent Craniopharyngioma

## Interventions

- **DRUG:** Tovorafenib

## Key facts

- **NCT ID:** NCT05465174
- **Lead sponsor:** Sabine Mueller, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-12
- **Primary completion:** 2027-03-01
- **Final completion:** 2028-03-01
- **Target enrollment:** 57 (ESTIMATED)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05465174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05465174, "Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05465174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*